2022-04-30-accounts - Heartburn Cancer UK

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

www.heartburncanceruk.org

HEARTBURN CANCER UK

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2022

Company Registered Number: 07227937 Charity Registered Number: 1136413

HEARTBURN CANCER UK ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

CONTENTS	PAGES
Officers and professional advisers	3
Trustees' report	4 to 9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Notes to the unaudited financial statements	13 to 21

HEARTBURN CANCER UK ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

OFFICERS AND PROFESSIONAL ADVISERS

Trustees	Mrs M E McCord
	Prof R C Fitzgerald
	Mr T Thornton-Jones
	Prof T J Underwood
	Mrs B A Huntingdon
	Dr O J Stovin
	Mr W Mathers
Business address and registered office	Grove House
	Lutyens Close
	Chineham Court
	Basingstoke
	Hampshire
	RG24 8AG
Independent Examiner	Mr N R Whitemore
	Hopper Willams & Bell Limited
	Highland House
	Mayflower Close
	Chandlers Ford
	Eastleigh
	Hampshire
	SO53 4AR

HEARTBURN CANCER UK TRUSTEES' REPORT (Incorporating Directors' Report)

YEAR ENDED 30 APRIL 2022

The trustees present their report and the unaudited financial statements of the charitable company for the year ended 30 April 2022.

The unaudited financial statements have been prepared in accordance with the accounting policies set out in note 1 to the unaudited financial statements and comply with the charity's governing documents, The Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to small charities preparing their accounts in accordance with the Financial Reporting Standards applicable in the UK and Republic of Ireland (FRE 102)" (as amended for accounting periods commencing from 1 January 2016).

Objectives and Activities

During the fiscal year 2021-22, Heartburn Cancer UK continued to work towards our well-defined mission and objectives as follows:

Mission

To be a respected UK source of awareness and information on the risks of ignoring persistent heartburn, encouraging the public to seek medical advice, to champion research to enable an earlier diagnosis to save lives, and to support those living with reflux, Barrett’s oesophagus and oesophageal cancer .

Our Objectives

For more information please visit our website at www.heartburncanceruk.org

Public Benefit

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

HEARTBURN CANCER UK TRUSTEES' REPORT (Incorporating Directors' Report)

(continued)

YEAR ENDED 30 APRIL 2022

Achievements and performance

Although COVID continued to influence FY21/22 it was very positive for the charity to return to some events and activities. Although this was accompanied by the reduction of income from COVID-related grant funds which had covered our income gap during 2020, and we have therefore not quite returned to what we would consider ‘normal’ operating conditions.

Fundraising

Various fundraising events including 'The Royal Parks' and our own Goodwood Golf Day was our top income stream for FY 21/22 raising over £49k .
Corporate Donations, trusts and foundations raised through partnerships including The Lanesborough, Albert Hunt, Arnold Clarke, The Chidwick Trust and BMS followed closely behind with over £41k.
Website income, including donations, in memory and merchandise, raised over £27k.
Legacies/In Memorium Giving raised through our partner, Much Loved, raised just over £6k.
The curtailment of normal life restricted our opportunities to raise funds via other partners such as Charity Traveller and Discover Adventure.
There was a minimal take up of our ventures into “Make a Difference Cards”, “Easy Fundraising” and “Amazon Smile”.

Patient Support

Support groups in East Anglia and London continued to be restricted & unable to meet in person but have continued to meet via Zoom to great effect for participants. Indeed, this new way of sharing information may see these groups able to expand their audiences as Covid 19 is consigned to history.
We are delighted to report our specialist Upper GI nurse from Basingstoke has been in touch to explore how we can resume the Basingstoke support group now it’s possible to meet in person again. This group had no appetite for staying in contact via Zoom during the pandemic.
Our online patient support group on Facebook has continued to grow and is now nearly four times the size it was last year with almost 150 members. There have been supportive and encouraging conversations between patients in a variety of situations. There are those who are undergoing investigation, those with a new Barrett’s diagnosis, patients who are post- oesophagectomy and are re-discovering eating as well as those who have been given a terminal diagnosis; a broad mix and some uplifting and widely helpful exchanges and support being constantly shared.
As well as having our clinical trustees Professor Rebecca Fitzgerald and Professor Tim Underwood to whom we can refer patient questions, this year we’ve expanded our team to include Sarah Davies as Dietician in Residence and Dr Oliver Stovin (Retd) as Doctor in Residence. The team has been busy reviewing information, offering additional content, answering patient questions and providing a useful blog with helpful information about everything from care pathways to health and lifestyle information.

HEARTBURN CANCER UK TRUSTEES' REPORT (Incorporating Directors' Report)

(continued)

YEAR ENDED 30 APRIL 2022

Achievements and performance (continued)

Research and Diagnosis

We have invested significant time and effort in working with the Project DELTA team at Cambridge, to bring our Mobile Diagnostic Unit (MDU) to life. It was important to provide assistance as required by the DELTA team. Many useful lessons have been learnt from our first location in Shelford, near Cambridge, and we have developed a good working relationship with our partners. The unit has now moved to its second of three locations (Essex) as part of this collaboration, and we have been able to secure some additional funding which will help provide further resources to increase the number of clinics we can operate. In turn we expect to expediate the waiting time between referral and Cytosponge testing for patients. The unit will move to its third location in Suffolk and will remain in situ until the end of this calendar year. The data and learning from this project will help feed our plans for a suitable collaboration to enable further use of the unit post DELTA and help the Cytosponge to be adopted into regular care pathways.
HCUK and the Association of Upper Gastrointestinal Surgery of Great Britain and Ireland (AUGIS) continue to co-fund the Surgical Specialist Lead (SSL) (Professor Tim Underwood) for oesophageal cancer through the RCSEng scheme. This role of Surgical Specialist Lead will help direct improvement of Oesophageal Cancer (OC) treatment and care and will continue in partnership with AUGIS.
Our chairman has spent much time and resource representing the charity and patients on numerous research projects, exemplified in writing letters of support, providing patient advocacy and lay representation in research projects, reviewing and editing documents to ensure their suitability for a lay audience. She is lay representative on the National Oesophago-gastric Cancer Audit (NOGCA).

General Awareness

Our raising of awareness has been maintained using our four social media platforms, Facebook, Twitter, LinkedIn and Instagram, which have seen ‘followers’ increase significantly this year. We take every opportunity to advertise and boost posts more widely as and when appropriate.
Our website continues as the mainstay of our awareness campaigning. This is signposted for social media and new materials regularly. We have continued to take advantage of the Google Ads grant available to us as a charity. Work with our web host has also resulted in new Search Engine Optimisation functionality being made available on the platform, and this is now being exploited.
To expand our helpful video library this year we have created some further productions in our collaboration with FaceTV. These include:
A short video about the Cytosponge.
A video capturing the mobile unit launch and patients undertaking the Cytosponge test.
An introduction to Professor Tim Underwood and the important role he plays as a surgeon and
surgical specialist lead for OC which HCUK funds.
4 short videos featuring Professor Tim Underwood answering questions commonly asked by patients
about Barrett’s & OC.
Further executions are planned for next year.
The charity enjoyed very positive PR coverage helping to raise awareness from our MDU launch in June 2021, particularly involving BBC local radio, BBC Look East & ITV news as well as local newspapers.

HEARTBURN CANCER UK TRUSTEES' REPORT (Incorporating Directors' Report)

(continued) YEAR ENDED 30 APRIL 2022

Achievements and performance (continued)

General Awareness (continued)

HCUK has just entered into a 2-year sponsorship agreement with six golf courses spread across the UK. This will see our messages shared in their clubs and amongst a prime audience of middle-aged men for the duration of the agreement, as well as offering the benefit of a ‘golf day’ at one club, with the twin aims of awareness and fundraising.

The past three years has been a step-change period for HCUK in terms of every aspect of our mission and objective delivery, and this against a backdrop of turmoil, in particular caused by Covid 19 since early 2020. Most significantly, our office team has expanded and we enjoy the services of a proficient group of dedicated individuals, committed to saving lives. We have found new routes to our audiences for both making target groups aware of the dangers of ignoring persistent heartburn as well as access to funds which ensure we can continue to spread this vital message. We have an excellent website, with evidence of it being accessed regularly and widely. Our social media presence has improved dramatically over the period mentioned, and our ability to generate larger donations has grown, particularly through Covid and with the development and execution of an effective vision and strategy encompassed by our Fundraising manifesto. We are better able to offer reliable advice to sufferers and their families, largely due to the expansion of our volunteer team to include our Dietician and Dr in Residence.

Financial Review

Total reserves are £158,244 (2021: £126,438), of this £74,023 is restricted and within restricted funds are held the fixed asset balance for the Mobile Diagnostic Unit. See note 17 for the detailed descriptions and balances on these funds.

Reserves Policy

It is the policy of the charity that unrestricted funds, which have not been designated for a specific use should be maintained at a level equivalent to six months' expenditure, which is calculated to be in the region of £43,000. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities whilst consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Risks

The Trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

Plans for the future

In FY23 we will be celebrating our 20th year as a charity, an achievement we are proud of. We intend to build on all our platforms to widen our influence and messaging. Re-deployment of our Mobile Diagnostic Unit in H2 after the end of the current ‘Delta Project’ collaboration/partnership will be a key focus for the team. With collaborations and partnerships in place we would look to procure a second unit, probably in early FY24 (though this can be flexible if funds & resources permit), such that we can grow geographically. We are exploring collaborations/partnerships with Cancer Alliances, Cyted and other interested parties. The Lanesborough Hotel and The Goodwood Charity Golf Day have raised funds specifically for this purpose which is much appreciated.

YEAR ENDED 30 APRIL 2022

HEARTBURN CANCER UK TRUSTEES' REPORT (Incorporating Directors' Report)

(continued)

Plans for the future (continued)

We will continue our awareness messages which encourage those suffering long-term heartburn to seek medical advice via appropriate PR, social media, our website and any other appropriate channel and opportunities. We will continue awareness messages in support of the Cytosponge as well as general awareness. There will also be messaging around the fact that 20 years has not seen enough change for early diagnosis and how wider use of the Cytosponge could really make a difference and help save lives.

A particular focus of activity in FY23 will be towards the cricketing community. The sad demise of Ray Illingworth at Christmas 2021 from OC offered an opportunity to work with prominent figures in the England and Wales Cricketing Community aimed at raising awareness amongst a key target group for the disease. We will expand on our successful PR work undertaken since then with further activity throughout the English cricket season.

We have also partnered with a golfing group with 6 courses across the UK for awareness activity, with another opportunity in the pipeline. Middle-aged men in the UK are a group overly affected by heartburn, and most likely to ignore the symptoms. This group watch cricket and play golf, and so by focussing on these two sporting areas we expect to be more effective in helping those affected by heartburn symptoms to seek treatment.

Our existing support groups and new Facebook help group have continued to provide an excellent service to users over the last year and we will continue to do everything necessary to widen their audiences and influence for the good of those living with Barrett’s or OC and their families. Support for patients is at the forefront of the work of the charity, and we will always prioritise efforts to provide this.

Our fundraising activities in FY22 continued to be strong but rather differently ‘shaped’ to what one might consider normal, impacted by the pandemic. As access to ‘emergency’ funds naturally diminishes as instances of Covid 19 decline, we become more reliant on both our traditional sources (In Memoria, legacies and affected people undertaking activities). We have managed to expand our network of potential funds over the course of the last three years and will look to exploit these. Success in our activities to generate such funds will enable us to achieve the more significant of our stated objectives.

Structure, governance and management

The following served as trustees during the year:

Mrs M E McCord Prof R C Fitzgerald Mr T Thornton-Jones Prof T J Underwood Mrs B A Huntingdon Dr O J Stovin (appointed 28 April 2022) Mr W Mathers (appointed 4 July 2022) Mr P R Carr (resigned 17 May 2022) Mrs J R M Carr (resigned 17 May 2022)

The above are also Directors for the purposes of company law.

The Board have the statutory power to appoint new trustees under the terms of the Trust Deed and provide the necessary training in order that they may fulfil their obligations as Trustees.

None of the Trustees has any beneficial interest in the company. The Directors, are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity is governed by the Board of Trustees which is responsible for formulating the strategies and policies of the charity including exercising financial controls.

HEARTBURN CANCER UK

TRUSTEES' REPORT (Incorporating Directors' Report)

(continued)

YEAR ENDED 30 APRIL 2022

Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with Company law requires the Trustees to prepare financial statements for each financial year. Under that law the

select suitable accounting policies and then apply them consistently;
make judgements and estimates that are reasonable and prudent;
observe the methods and principles in the Charities SORP;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping proper accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Signed on behalf of the Board of Trustees

Mrs M E McCord Chair of Trustees

Approved by the board on: 26th January 2023

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF

HEARTBURN CANCER UK

YEAR ENDED 30 APRIL 2022

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 April 2022, which are set out on pages 11 to 21.

Respective responsibilities of Trustees and examiner

As the charity’s trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (the ‘2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's report

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1) accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2) the accounts do not accord with those accounting records; or
3) the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair’ view which is not a matter considered as part of an independent examination; or
4) the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr N R Whitemore

Hopper Willams & Bell Limited Highland House Mayflower Close Chandlers Ford Eastleigh Hampshire SO53 4AR Date: 26th January 2023

HEARTBURN CANCER UK STATEMENT OF FINANCIAL ACTIVITIES including INCOME AND EXPENDITURE ACCOUNT YEAR ENDED 30 APRIL 2022

Notes Income from: Donations and legacies 2 Fundraising activities 3 Investments 4 Total incoming resources Expenditure on: Costs of generating funds 5 Charitable activities 6 Governance costs 10 Total resources expended Net (expenditure)/income for the year/net movement in funds Fund balances as at 1 May 2021 Fund balances as at 30 April 2022 17	UnrestrictedRestricted General funds 56,568 73,524 651 37,143 12 - 57,231 110,667 26,029 22,987 32,043 53,905 1,128 - 59,200 76,892 (1,969) 33,775 86,190 40,248 84,221 74,023	2022 £ 130,092 37,794 12 167,898 49,016 85,948 1,128 136,092 31,806 126,438 158,244	2021 £ 123,118 1,138 41
			124,297 28,253 75,860 48
			104,161
			20,136 106,302
			126,438

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure relates to continuing activities.

The statement of financial activities also complies with the requirements of an income and expenditure account under the Companies Act 2006.

The notes on pages 13 to 21 form part of these financial statements.

HEARTBURN CANCER UK BALANCE SHEET

Registered Number 07227937 AS AT 30 APRIL 2022

Note Fixed Assets 14 Current Assets Other debtors 15 Cash at bank and in hand Creditors: Amounts falling due within one year 16 Net current assets Total assets less current liabilities Net assets Represented by: Income Funds Restricted funds 17 Unrestricted Funds - Designated funds 17 - General unrestricted funds 17	2022 £ 21,646 21,646 36,666 117,777 154,443 (17,845) 136,598 158,244 158,244 74,023 - 84,221 158,244	7,203 92,735	2021 £ 27,058
			27,058 99,380
		99,938 (558)

			126,438
			126,438
			40,248 - 86,190
			126,438

The charitable company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 30 April 2022. No member of the charitable company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act with respect to accounting records and the preparation of accounts. These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with FRS102 SORP.

These financial statements were approved by the Trustees and authorised for issue on 26th January 2023, and are signed on their behalf by:

Mrs M E McCord Chair of Trustees

The notes on pages 13 to 21 form part of these financial statements.

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

1 Accounting policies General information

Heartburn Cancer UK ("the charitable company") has prepared financial statements covering its results for the year to 30 April 2022. The charitable company has presented its financial statements in Sterling, rounded to the nearest whole pound.

The charitable company is a private company limited by guarantee and is incorporated in England and Wales. The address of the charitable company's registered office is presented on page 3 of these financial statements under Officers and Professional Advisors. The charitable company's principal activities and nature of the business are shown on page 4.

Basis of accounting

The financial statements have been prepared under the historical cost convention, in accordance with the charity's governing document, the Companies Act 2006, as applicable to companies subject to the small companies regime, "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with FRS102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("SORP") and with the Charities Act 2011. The principal accounting policies adopted are set out below. The charity is a Public Benefit Entity as defined by FRS 102.

Statement of Cashflows

The charitable company has taken advantage of the provisions in the SORP for charities applying FRS102 update Bulletin 1 not to prepare a Statement of Cashflows.

Going concern

At the time of preparing the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

Charitable Funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated, by the Trustees, for other purposes. Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donor that the capital must be maintained by the charity.

Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Donations by way of grants are recognised either on receipt or Invoice, whichever is earlier. Donations and associated gift aid from on-line sites such as Just Giving and Virgin Giving are recognised as and when paid by those sites, after they have been verified and processed, and includes donations remitted to the charity from those sites within the financial year. These donations are recorded net of processing charges.

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

1 Accounting policies (continued)

Other donations and legacies are recognised on receipt. Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

Donated services and facilities are included in the Statement of Financial Activities in the year they are received at the value of the gift to the charity, provided the value of the gift can be measured reliably. The expense element of such donations is reflected in resources expended in the appropriate expense category.

Resources expended

Costs of generating voluntary income comprise the costs incurred by the charity to induce others to make donations to the charity.

Activities in furtherance of charitable objectives undertaken directly relate to expenditure incurred as a direct result of undertaking the charitable objectives of the charity.

Governance and core activities expenditure

Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice.

Core Activities Expenditure are those costs incurred directly in support of the objects of the charitable company and fundraising and are allocated to activity cost categories on a basis consistent with the use of resources.

Tangible fixed assets

Tangible fixed assets are stated at cost less depreciation. Cost represents purchase price together with any incidental costs of acquisition.

Depreciation

Depreciation is calculated so as to write off the cost of an asset, net of anticipated disposal proceeds, over the useful economic life of that asset as follows: - Mobile Diagnostic Unit straight line over 5 years

Financial Instruments

The charitable company only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measure at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Critical accounting estimates and areas of judgement

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimated and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

2 Donations and legacies Unrestricted funds Donations and gifts 46,174 Donations in Kind 10,394 56,568 3 Fundraising activities Sale of Christmas Cards Golf Day Income (restricted) 4 Investments Interest receivable 5 Costs of generating funds Printing and advertising Website and social media Fund raising activities Golf Day expenditure (restricted) Other expenditure See note 8 for further details 6 Expenditure on Charitable Activities Unrestricted funds Grant funding of activities - Other expenditure 32,043 32,043 Analysis by fund for 2021 45,860 7 Grants payable Unrestricted funds To fund a surgical specialty lead - -	Restricted funds 70,524 3,000	2022 £ 116,698 13,394	2021 £ 112,544 10,574
56,568	73,524	130,092	123,118
	Restricted funds 3,125 50,780	2022 £ 651 37,143	2021 £ 1,138 -
		37,794	1,138
		2022 £ 12	2021 £ 41
		2022 £ 1,138 1,032 4,566 22,987 19,293	2021 £ 1,233 1,296 2,714 - 23,010
		49,016	28,253
		2022 £ 3,125 82,823 -	2021 £ 7,500 68,360 -
32,043	53,905	85,948	75,860
			2021 £ 7,500
45,860	30,000	75,860
	Restricted funds 3,125	2022 £ 3,125
-	3,125	3,125	7,500

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

8 Core activities expenditure analysis for the year Fundraising MDU operation £ £ Staff costs 15,242 10,684 Travel costs and training 100 - Grants awarded - - Consumables - 5,203 MDU Depreciation - 5,412 Office space 2,639 1,850 Printing and advertising 1,138 - Website and social media 1,032 - IT and computer expenses 648 454 Postage, courier and telephone 167 117 General fundraising costs 4,566 - Office supplies 16 11 Insurance - 1,203 Bank charges 446 - Subscriptions - - Sundries - - Regulatory and governance costs 35 - Golf day event costs 22,987 - 49,016 24,934 Total expended resources for the year to 30 April 2022	8 Core activities expenditure analysis for the year Fundraising MDU operation £ £ Staff costs 15,242 10,684 Travel costs and training 100 - Grants awarded - - Consumables - 5,203 MDU Depreciation - 5,412 Office space 2,639 1,850 Printing and advertising 1,138 - Website and social media 1,032 - IT and computer expenses 648 454 Postage, courier and telephone 167 117 General fundraising costs 4,566 - Office supplies 16 11 Insurance - 1,203 Bank charges 446 - Subscriptions - - Sundries - - Regulatory and governance costs 35 - Golf day event costs 22,987 - 49,016 24,934 Total expended resources for the year to 30 April 2022	MDU operation £ 10,684 - - 5,203 5,412 1,850 - - 454 117 - 11 1,203 - - - - -	Awareness £ 13,338 - - - - 2,310 7,093 9,285 567 146 - 14 - - - - - -	Research £ 3,396 - 3,125 - - 588 - - 144 37 - 4 - - - - - -	Support Groups £ 7,352 - - - - 1,273 - - 312 81 - 8 - - - - - -	General support £ 9,163 - - - - 1,587 - - 389 100 - 10 190 308 - 229 1,093 -
	49,016	24,934	32,753	7,294	9,026	13,069
						136,092

Total expended resources for the year to 30 April 2022

9 Allocation of costs to funds

Staff Costs Travel costs Grants awarded Consumables MDU Depreciation Office space Printing and advertising Website and social media IT and computer expenses Postage, courier and telephone Fundraising Office supplies Insurance Bank charges Subscriptions Sundries Regulatory and governance costs Golf day event costs	2022 £ £ £ Total Unrestricted Restricted 59,175 42,060 17,115 100 100 - 3,125 - 3,125 5,203 - 5,203 5,412 - 5,412 10,247 6,087 4,160 8,231 1,138 7,093 10,317 1,032 9,285 2,514 1,493 1,021 648 385 263 4,566 4,566 - 63 38 25 1,393 190 1,203 754 754 - - - - 229 229 - 1,128 1,128 - 22,987 - 22,987 136,092 59,200 76,892 2022 Allocation	2022 £ £ £ Total Unrestricted Restricted 59,175 42,060 17,115 100 100 - 3,125 - 3,125 5,203 - 5,203 5,412 - 5,412 10,247 6,087 4,160 8,231 1,138 7,093 10,317 1,032 9,285 2,514 1,493 1,021 648 385 263 4,566 4,566 - 63 38 25 1,393 190 1,203 754 754 - - - - 229 229 - 1,128 1,128 - 22,987 - 22,987 136,092 59,200 76,892 2022 Allocation	2022 £ £ £ Total Unrestricted Restricted 59,175 42,060 17,115 100 100 - 3,125 - 3,125 5,203 - 5,203 5,412 - 5,412 10,247 6,087 4,160 8,231 1,138 7,093 10,317 1,032 9,285 2,514 1,493 1,021 648 385 263 4,566 4,566 - 63 38 25 1,393 190 1,203 754 754 - - - - 229 229 - 1,128 1,128 - 22,987 - 22,987 136,092 59,200 76,892 2022 Allocation	2021 £ 53,212 75 7,500 - - 10,574 12,331 12,962 2,697 549 2,714 59 444 590 120 286 48 -
	136,092	59,200	76,892	104,161

Costs are allocated to funds on the basis of either actual costs incurred or estimated resource usage.

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

10 Governance Costs

Legal and Professional fees Independent examiner's fee 11 Staff costs Salaries and wages Pension costs No staff receive more than £60,000 per annum. Average number of full time equivalent staff in the year Fundraising Charitable activities Other Average (absolute) number of staff in the year	2022 £ 48 1,080	2021 £ 48 -
	1,128	48
	2022 £ 56,269 2,906	2021 £ 52,084 1,128
	59,175	53,212
	2022 FTE No 0.5 1.0 0.3	2021 FTE No 0.6 0.8 0.3
	1.8	1.7
	2022 No 3.2	2021 No 3.0

12 Trustees

None of the Trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

HEARTBURN CANCER UK NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

13 Related Party Transactions

During the year Absolutely Offices Limited, of which Beryl Huntingdon, a trustee of the charitable company, is a director, provided the following services to the charity on normal commercial terms.

Computer expenses Postage, courier and telephone Office supplies and sundry expenses Office space Printing and advertising	2022 £ - 462 12 202 29	2021 £ - 196 - - 41
	705	237

In addition, Absolutely Offices Limited provided the following services free of charge as a donation in kind:

Office space 14 Tangible fixed assets Cost At 1 May 2021 Additions At 30 April 2022 Depreciation At 1 May 2021 Charge for the period At 30 April 2022 Net book value At 30 April 2022 At 1 May 2021 15 Other debtors Other debtors Prepayments and accrued income	2022 £ 10,044	2021 £ 10,044
	10,044	10,044
	£ 27,058 - Mobile Diagnostic Unit	Total £ 27,058 -
	27,058	27,058
	- 5,412	- 5,412 -
	5,412	5,412
	21,646	21,646
	27,058	27,058
	2022 £ - 36,666	2021 £ - 7,203
	36,666	7,203

HEARTBURN CANCER UK

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

Balance at 1 May 2021 £ -	2022 £ - - 17,845 17,845 Incoming resources Resources expended Transfers £ £ £ - - - - - - 57,231 (59,200) - 57,231 (59,200) - Movement in Funds	2022 £ - - 17,845 17,845 Incoming resources Resources expended Transfers £ £ £ - - - - - - 57,231 (59,200) - 57,231 (59,200) - Movement in Funds	2022 £ - - 17,845	2021 £ 324 234 -
			17,845	558
				Balance at 30 April 2022 £ -
-	-	-	-	-
86,190	57,231	(59,200)	-	84,221
86,190	57,231	(59,200)	-	84,221

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

HEARTBURN CANCER UK

YEAR ENDED 30 APRIL 2022

17 Statement of Funds (continued)

Restricted Funds HCUK Augis RCS Cytosponge Mobile Diagnostic Unit - operation Cytosponge Mobile Diagnostic Unit - Essex & Suffolk Cytosponge Mobile Diagnostic Unit - purchase Staff Costs Return to fitness Awareness - North West of England Awareness - London HCUK East Anglia Awareness	Balance at 1 May 2021 £ 3,125 31,370 - - - 1,000 2,102 500 2,151 - 40,248	Incoming resources Resources expended £ £ - (3,125) 34,677 (24,933) 10,000 - 40,143 (22,987) 3,000 (3,000) - - - - - - - - 22,847 (22,847) 110,667 (76,892) Movement in Funds	Balance at 30 April 2022 £ - 41,114 10,000 17,156 - 1,000 2,102 500 2,151 -
			74,023

HCUK AUGIS Royal College of Surgeons

To help fund a Surgical Speciality Lead in the field of Oesophageal Cancer.

Cytosponge Mobile Diagnostic Unit - operation

To fund the purchase of a Mobile Diagnostic Unit and related equipment, which are accounted for as fixed assets and will be depreciated from May 2021, and fund the running costs of the unit. The unit is currently being deployed to support the DELTA project to demonstrate the efficacy of the "Cytosponge" in promoting early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus.

Cytosponge Mobile Diagnostic Unit - operation in Essex and Suffolk

To operate the mobile diagnostic unit in delivering the "Cytosponge" in promoting early diagnosis of Oesophageal Cancer and/or Barrett's Oesophagus in the Essex and Suffolk regions.

Cytosponge Mobile Diagnostic Unit - purchase

Funds raising from the Golf Day event arranged to fund the purchase of an additional Mobile Diagnostic Unit and related equipment.

Staff costs

To fund staff costs during and following the Covid crisis period.

Return to fitness

To support a research project into a programme to support Oesophageal Cancer patients recovering after treatment.

Awareness - North West of England

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the North West of England.

Awareness- London

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus, in the London area.

HCUK East Anglia

To fund the activities of the East Anglia support group with funds generated by the support group itself.

Awareness

Fund to raise awareness in patients and physicians of the link between persistent heartburn and Oesophageal Cancer and/or Barrett's Oesophagus.

HEARTBURN CANCER UK

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

YEAR ENDED 30 APRIL 2022

18 Analysis of net assets between funds

Analysis of net assets between funds
Fixed Assets Net current assets Net assets Fund balances at 30 April 2022 are respresented by:	Unrestricted funds - 84,221 84,221	Designated funds - - -	Restricted funds 21,646 52,377 74,023	Total £ 21,646 136,598
				158,244

19 Ultimate controlling party

The trustees do not consider there to be an ultimate controlling party other than the Board of Trustees.